April 27, 2012
Hudson headquarters not spacious enough.
Purchase will expand the company's cytometry business.
The anti-hacking device is still in its beginning stages.
Company adds to manufacturing footprint in the United States and opens new facility in Costa Rica.
The HSA revises its brand new device registration rules.
First quarter analysis shows earning are up slightly from last year.
JNJ expects the merger to be complete in Q2.
David Dvorak discusses association's three-year advocacy plan.
SynGen gets $5 million to fuel stem cell harvesting devices.
CEO steps down as the company moves ahead in the weight loss sector.
The company progresses in the heart sector despite recent lead wire controversy.
Complexities of law and the wording of his claim prohibit paraplegic Richard Stengel from suing.
Kenneth Marshall joins Aerocrine from Ikaria.
Nurses anticipated to benefit from the system's ease of use.
The surgical navigation system will pair with Neurologica's BodyTom CT scanner
The Ellipse ICD receives CE Mark approval.
The company claims Powerease reduces fatigue in surgeons.
The ISPAB warns about danger, while researchers get closer to preventing the problem.
Cofounder steps down from the post after fourteen years.
The study will take place in 55 U.S. cities, and is already underway in Europe.
The biopolymer scaffolding device is hoped to be the first effective treatment for spine-related paralysis.
The system should detect cancer better and earlier, company claims.
In another shuffle, Philips faces some challenges in the face of a drop in demand for its healthcare products.
Thrower and Steuben bring experience from other industry leaders.
Donald Casey will assume his post on April 16th.
The sheath will be used to position catheters within the heart.
Wounded warriors look ahead to possible improved rates of limb salvaging.
The device utilizes suction pressure to accelerate healing.
The CRT-D devices will puportedly reduce mortality rates in early-stage heart failure risk patients.
Accusations fly as the company struggles against bad PR and falling share prices.
Local customers will enjoy easier access to company products.
All three devices treat end stage renal disease.
The FDA currently is reviewing the devices for the U.S. market.
Randall Barko comes with 30 years experience in the business.
The acquisition will bring breathing-assistance devices to Covidien.
Though not a recall, the letter warns physicians to be vigilant in their monitoring of affected implanted cardio devices.
Thoratec claims it is more of a correction than a recall.
85 year old patient experienced chest pain relief.
The report finds increased review times.
Move comes amidst Johnson and Johnson's negotiation with European antitrust authorities.
Merger expected to be finalized within three months.
Company denies any wrongdoing.
The combination product is made up of a gel that works together with a catheter.
Acquisition valued at $14.5 million.
Please visit our sister sites:
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.